Good morning, and welcome to Auna's First Quarter 2025 Earnings Conference Call. My name is Rob, and I will be the operator for today's call. [Operator Instructions] And please note that this call is being recorded. [Operator Instructions] Now I would like to turn the call over to Ana Maria Mora, Head of Investor Relations. Ma'am, please go ahead.

Thank you, operator. Hello, everyone, and welcome to Auna's conference call to review our first quarter results. Please note that there is a webcast presentation to accompany the discussion during this call. If you need a copy of the presentation, please go to our Investor Relations website or contact Auna's Investor Relations team. Please note that when we discuss variances, we will be doing so on a year-over-year basis and in FX neutral, or local currency terms with regards to Mexico and Colombia, unless we know it otherwise. Let's move to Slide 2. In addition to reporting unaudited financial results in accordance with International Financial Reporting Standards, we will discuss certain non-IFRS financial measures and operating metrics including foreign exchange neutral calculations. Investors should carefully read the definitions of these measures and metrics included in our earnings press release of yesterday to ensure that they understand them. Non-IFRS financial measures and operating metrics should not be considered in isolation as substitute for superior to IFRS financial measures, and are provided as supplemental information only. Before we begin our remarks, please also note that certain statements made during the course of today's discussion may constitute forward-looking statements, which are based on management's current expectations and beliefs. And which are subject to a number of risks and uncertainties that could cause actual results to materially differ, including factors and maybe beyond the company's control. These include, but are not limited to, our expected adjusted EBITDA growth, the expected impact on revenues and profitability of certain initiatives we are pursuing in Mexico and long-term financial position and flexibility as a result of certain initiatives we are pursuing related to payers in Colombia and our target leverage level. For a discussion of these risks, please refer to our Form 20-F filing with the U.S.…

Thank you, Jesus. My review begins with revenue contributions on Slide 11. As Jesus highlighted, Peru helped partially offset the first quarter decrease in Mexico's revenue. Peru's 10% revenue increase was mainly driven by higher surgery volumes and improved pricing during the quarter, which you also see reflected in higher capacity utilization. At OncoSalud our health plan business in Peru, revenue was driven by annual inflation price adjustments and a 10% increase in planned memberships. In the case of Colombia, the implementation of risk-sharing models was in part behind the 5% revenue increase in local currency. These are upfront payments for high complexity services such as cardiology and oncology services. Another factor in the revenue growth was the diversification of our payer portfolio, as we are proactively managing our contracted services and diversifying our payer mix, which is another way we have been mitigating risk and preserving cash flow in Colombia. Let's now turn to Slide 12, please. As Jesus explained, Mexico's revenue decline and additional impairment provisions in Colombia slowed EBITDA growth and compressed our margin, which finished the quarter, 1 percentage point down versus the first quarter of 2024. Helping offset the lower profitability in Mexico and Colombia was the 19% increase in Peru's adjusted EBITDA. That increase and the 1.7 percentage point margin expansion reflects the top line growth and efficiency gains of our most mature and scaled business. It's important to note that despite the volume decrease in Mexico and the capacity investments that we've been making in this market, this segment's adjusted EBITDA margin remained high at a healthy 33.2%. Let's now move to Slide 13, please. We delivered our fifth consecutive quarter of positive adjusted net income. On this slide, we break down this PEN 33 million increase from the first quarter of 2024…

[Operator Instructions] Your first question comes from the line of Mauricio Cepeda from Morgan Stanley.

I would like first to ask about Mexico. If I understood correctly, it's almost a cleanup of the relations you have with the physicians and suppliers there, a little bit more towards the AunaWay. So in that regard, why trying to make this kind of transition at this point in time? What led to the decision to make this kind of transition now? And if you foresee that a ramp-up out of this transition would be something to happen in the short term? Or is something that you foresee to happen a little bit more towards the medium term. And the second question is about Colombia. If you could update on the conversations, you're having there with the interventions there, if there is any room for further risk sharing agreements there? Jesús Zamora Leon: Thank you, Mauricio, and nice to hear you. On Mexico, I would not want to consider what you said a cleanup. As I indicated before, the AunaWay is transformational. And it's tough for physicians that are so well integrated into the supplier chain. So the main source of lost volumes would be to close -- this close relationships between the suppliers and physicians. This is critical for the AunaWay, and this is critical for our focus on high complexity. And this is very important, specifically in our relations with the payers. We are a unique player that has high credibility from insurance companies because we control, and we are very predictable on what happens in the clinical aspects of health care and the patient journey of health care and also in our margins. So this is not another thing that can be postponed, but has to be managed gradually to make sure that our volumes do not decrease, and then we continue to grow and penetrate especially high complexity, higher margin services. So I would say that and that is critical, Mauricio. I think that in Colombia, in respect to our risk-sharing models, we are now approximately 20% of our revenues is in risk-sharing model. You must may recall, Mauricio, that this was something like 15% last year, and we are targeting 30% towards the end of the year and even more in mid next year. This is consistent with our strategy to favor cash flows as payment terms are very favorable and margins are stable, I would say. Thank you, Mauricio.

And there are no more questions on the phone line. So I will now turn the call over to Ana Maria Mora from Auna, who will proceed with the questions from the webcast platform.

Thank you, operator. So the first question comes from Alex Stevenson. Please provide more detail about what has happened with operations in Mexico. Jesús Zamora Leon: Great. Thank you very much, Alex, for that question. So again, the main source of lost volumes was due to this close relationship between suppliers and physicians. Our model, as I said, is disruptive. It challenges many intrinsic practices, in particular, traditional practices that aren't easy to accept by some physicians. Our model allocates high volume to doctors who abide to our medical practices, and this does take some time and months to implement. Now what I'd like to represent, I think the important part is that we have reacted quickly, and we are already in the process of seeing and harvesting some of the results of our action. Now we are, as I indicated before, noting a recovery in volumes, but of course, this is a work in progress. We are confident in the recovery in the coming quarters, but it is early to quantify. These are coming from a variety of practices, medical practices especially on those that we are focused on and high complexity again to have a higher dependence also on medical devices. So getting this right is something important. This is also something that we have confronted in the past, this is not something unique to Mexico to Monterrey health care in the world is fraught with the challenges of fee-for-service models, highly incentivized by big pharma and medical device manufacturers. Our model disrupts this, and it works, but it needs to be implemented gradually. This is not a problem, it is a well-known hurdle in the industry, dealing with it as part of the process of transforming the market and makes Auna much stronger. And it's something that we've done in the past as well. Thank you, Alex.

Thank you, Jesus. The next question comes from [indiscernible]. Thank you for the call. Could you please share how your guidance for Mexico has evolved compared to the initial expectations? Jesús Zamora Leon: So recently we discuss a lot internally. Given that we manage the company ever integrated regional play. We have -- we have not given guidance by country. We have given guidance in the past about the consolidated results, Auna. But early this year, we decided to make sure that the market understood that Colombia, in particular, and now Mexico has given us enough factors to say, let's wait off before we give guidance further for the year now. We have an internal target, and I've discussed it in the past, a full year EBITDA growth of 20%. We have been doing more -- 20% or more over a decade. However, as I indicated right now at the beginning of the year, we are reluctant to call it a guidance because of what was occurring in Colombia, that was outside of our control. Now given in first Q results in Mexico, we need to see how the recovery they shapes up in the next few quarters to have a better visibility in the full year, but we are confident we will recover our growth and our growth trajectory in Mexico in the coming quarters. So I don't think we're changing the way we manage the business, the way we project the business, the way we budget the business, no. But we're being a little -- we're being very conservative in what we want to call our guidance. Our expectation in Mexico just to be a little more conceptual on that. Our expectation in Mexico is within where we expect. We manage the business with stable margins and a growing penetration of high complexity volume. That's happening this quarter. We had this reversal, but that's generally happening since we took over the operations. We have a great opportunity in Mexico. We still have a lot of capacity to use. We have a greater -- you may recall, what we represented them last quarter with our acquisition of the Opcion Oncologia Group in Monterrey, that's already seen a very interesting results at Doctors Hospital in Monterrey. So we're growing and we want to grow, and we want to make sure that it's stable and it actually has a qualitative impact on how we deal with physician practices and the physician integration into the suppliers. Thank you very much, [indiscernible].

Thank you, Jesus. The next question comes from [indiscernible] and it is -- what is your EBITDA and CapEx guidance for 2025? Do you expect additional impairments in Colombia in 2025. What is the current status of the deployment of OncoSalud in Mexico?

Thank you, Annie. I can take the first part of that call above that question, maybe pass it over to Jesus to talk a little bit about OncoSalud in Mexico. I think Jesus already answered the question on EBITDA guidance, which we did not give specific EBITDA guidance for the year. As far as CapEx guidance, this continues to be the same levels that we've seen in previous years, which should be at or below $50 million annually for CapEx investments in the regular course of business. In the case of provisions in Colombia, as we previously mentioned, our policy continues to be based on an expected loss model, and there is a differentiated treatment for the intervened entities. We will continue to see impairments in accounts receivable in the coming quarters. But as previously mentioned, this does not reflect the view that we won't be able to collect on those accounts. It's just a matter of derisking the balance sheet basically through the coming quarters. But we still remain confident and constructive on the medium-term outlook and on the fact that we will be collecting on those accounts. Jesus, I don't know if you want to complement on the progress of OncoSalud in Mexico. Jesús Zamora Leon: Sure. Thank you very much, Gisele. And thank you very much, Omar. So again, we continue to be very excited about OncoMexico -- OncoSalud in Mexico. We have a very strong pipeline. I've spoken about this in last quarter, and I think that we made really good progress in closing the network outside of Monterrey, which is a key deliverable from most of the prospective large clients that want to be covered by OncoMexico, that is outside of Monterrey. In this quarter, we have already secured a national network in three major cities in addition to Monterrey, of course, in Mexico City. In Guadalajara, I was in Tijuana day before yesterday on Monday, and we're closing on Tijuana this month. So the market should read this as very positive for OncoMexico, given that we're closing these agreements on this platform of services, in -- we will have it in the four principal cities of Mexico, no further benefit of the pipeline that we have that is also, of course, demanding on national coverage. So we are -- we don't give guidance on OncoMexico, but I clearly -- clear and very optimistic. And as you can tell from what we're closing in terms of this network, this is definitely related to demand from this pipeline that I represented before. Thank you, Omar.

Thank you, Jesus. The next question comes from [indiscernible]. Could you share your outlook on capital expenditures for the rest of the year? And do you see the effective tax rate stabilizing around 30% level this year?

Thank you for the question. I think the CapEx part was already answered with the outlook basically being at or below $50 million for the full year. And in the case of the effective tax rate, which has -- I think last year, it was around 33%. This year, we expect it to be closer to around 38%, this having to do also with when you make payments intercompany in the subsidiaries of the group, you do have some tax effects. We continue to recognize deferred tax benefits in the effective tax rate, which should lead to an improved tax cash rate in the coming years, which I think will also be very positive for liquidity.

Thank you, Gisele. The next question comes from [indiscernible]. Could you please elaborate the business development expenses in Mexico. Is this related to OncoMexico and will this continue in coming quarters?

So the approximately PEN 27 million in business development expenses, which were adjusted from EBITDA in the first quarter correspond to the upfront payments made to the doctors from Opcion Oncologia, who joined us in March. Those payments will be made throughout 2025, but they were recognized as part of the expenses in the accounting EBITDA in the first quarter and are completely nonrecurring and only due to an upfront payment. Jesús Zamora Leon: And I would just add on [indiscernible]. And yes, they are related to OncoMexico. Of course, because we manage the oncology platform as an integrated platform on the insurance and Opcion Oncologia, which is the platform of services that are our center of excellence for oncology.

Thank you, Jesus. Thank you, Gisele. The last question comes from Caio Moscardini. How long did it take for the AunaWay to be fully accepted by suppliers and physician when you get -- when you started its implementation in Peru? Jesús Zamora Leon: Well, that's a very good question, Caio. So in Peru, it took various years. In Colombia, it was a little quicker. And in Mexico, we expect it to be also quicker than what we've seen in Peru. Given that we've learned and given that we scale that we have today in terms of engaging suppliers directly and not through that with third-party intermediaries that are the ones that are integrated into -- into the physicians themselves. This is the way we manage, it Caio, is practice by practice. Orthopedics and trauma has a big component of integration. Cardiology, a little bit as well, some surgical procedures, and we manage by practice and by supplier. And gradually, gradually because it's very important to recognize doctors has a total income -- family income, let's call it, that includes the payments they get from this integration. So we have to be careful, and we have been careful in the past in -- since this helping them better transition their total income from suppliers to Auna and their own personal physician practices. Thank you, Annie.

Thank you, Jesus. At this time, I'm not showing any more questions. Maybe I would like to turn the call back over to Jesus for the closing remarks. Jesús Zamora Leon: Thank you very much, Annie. Just in finalizing, we have had a bump in the road. We're in control. The model is disruptive as I made the case on occasion. It is -- I'd like to call it a threshold event once you get the model going, it scales, it reaps, the benefit for both patients and doctors and of course, for Auna. I thank the investor community for your commitment to Auna and to the community behind Auna. I want to thank you for your attention on this call. Thank you very much.

This concludes today's conference call. You may now disconnect.